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Abstract
Background: We hypothesized that, in patients with pulmonary fibrosis combined with emphysema, clinical
characteristics and outcomes may differ from patients with pulmonary fibrosis without emphysema. We identified
102 patients who met established criteria for pulmonary fibrosis. The amount of emphysema (numerical score) and
type of emphysema (centrilobular, paraseptal, or mixed) were characterized in each patient. Clinical characteristics,
pulmonary function tests and patient survival were analysed.
Results: Based on the numerical emphysema score, patients were classified into those having no emphysema
(n = 48), trivial emphysema (n = 26) or advanced emphysema (n = 28). Patients with advanced emphysema had a
significantly higher amount of smoking in pack/years than patients with no emphysema or trivial emphysema
(P < 0.0001). Median survival [1st, 3rd quartiles] of patients with advanced emphysema was 63 [36, 82] months
compared to 29 [18, 49] months in patients without emphysema and 32 [19, 48] months in patients with trivial
emphysema (P < 0.001). Median forced vital capacity (FVC) and total lung capacity (TLC) were higher in the
advanced emphysema group compared to patients with no emphysema (P < 0.01 and P < 0.001, respectively),
whereas median DLCO did not differ among groups and was overall low. Within the advanced emphysema group
(n = 28), further characterization of the type of emphysema was performed and, within these subgroups of
patients, survival was 75 [58, 85] months for patients with centrilobular emphysema, 75 [48, 85] months for patients
with mixed centrilobular/paraseptal emphysema, and 24 [22, 35] months for patients with paraseptal emphysema
(P < 0.01). Patients with advanced paraseptal emphysema had similar survival times to patients without
emphysema.
Conclusions: Patients with pulmonary fibrosis combined with advanced centrilobular or mixed emphysema have
an improved survival compared with patients with pulmonary fibrosis without emphysema, with trivial emphysema
or with advanced paraseptal emphysema.
Background
Pulmonary fibrosis is a major component of various dif-
fuse parenchymal lung diseases, including idiopathic
pulmonary fibrosis (IPF) and other forms of idiopathic
interstitial pneumonia. Pulmonary fibrosis results in sub-
stantial morbidity and mortality and therapies have been
uniformly poorly effective [1,2].
Histological changes in the lungs of patients with IPF
show usual interstitial pneumonia (UIP), a pattern of
fibrosis characterized by fibroblastic foci and excessive
deposition of extracellular matrix. Initial hypotheses for
the mechanism of IPF focused on the role of inflamma-
tion and most authorities believed that pulmonary
inflammation was a prominent and necessary feature of
the UIP process [3-5]. More recently, however, the role
of inflammation has been questioned and, although the
precise aetiology of IPF remains unknown, most experts
presently state that active cellular lung inflammation is
not a major feature or requirement for the development
of UIP [4]. Furthermore, in addition to inflammation
being considered nonessential for the development of
IPF/UIP, a hypothesis was proposed that inflammation
may actually be beneficial in this disease process [5].
Observations in human patients and animals provide
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tive tissue diseases such as systemic sclerosis develop
pulmonary fibrosis but this occurs in association with
autoimmune inflammation and the survival of patients
with interstitial pneumonia associated with connective
tissue diseases is longer than patients with IPF [6,7]. We
previously reported that lymphocytic inflammation
induced by gene delivery of chemokine CCL18 is par-
tially protective against the severe fibrosis caused by
administration of bleomycin in mice [8]. Based on these
considerations, we hypothesized that patients with IPF
combined with a chronic inflammatory process may be
partially protected from the usual rapidly declining clini-
cal course. One example of a well-established chronic
inflammatory pulmonary disease is emphysema [9-11].
Emphysema is most commonly caused by cigarette
smoking [9] and the inflammatory component of
emphysema may be only partially reversed after smoking
cessation [11].
We specifically hypothesized that patients with com-
bined pulmonary fibrosis and emphysema may have dif-
ferent clinical characteristics and outcomes than
patients with pulmonary fibrosis in the absence of
emphysema. In this study, we determined the presence
or absence of emphysema, along with its severity and
type, in a cohort of patients with pulmonary fibrosis and
characterized their clinical characteristics, pulmonary
physiology and overall outcomes.
Methods
Patients
The study was reviewed and approved by the University
of Maryland Institutional Review Board (Human
Research Protection Office, Protocol HP-00044077).
Patients with interstitial pneumonia were identified at
the University of Maryland either through direct patient
care visits or through ICD-9 code review for ‘interstitial
lung disease’. Following our review, 102 patients were
identified who met either (1) established criteria for
definite or confident idiopathic pulmonary fibrosis (IPF)
or (2) established clinical and pathologic criteria for
idiopathic fibrotic NSIP (fibrotic non-specific interstitial
pneumonia) [1,2]. Patients with following diagnoses
were not included in this cohort: (a) other forms of idio-
pathic interstitial pneumonia( c r y p t o g e n i co r g a n i z i n g
pneumonia, respiratory bronchiolitis-interstitial lung dis-
ease, acute interstitial pneumonia and desquamative
interstitial pneumonia); (b) connective tissue disease-
interstitial pneumonia; (c) sarcoidosis; (d) hypersensitiv-
ity pneumonitis; and (e) pneumoconiosis.
Computed tomography (CT) of the chest, patient
demographics and clinical characteristics, lung pathol-
ogy, pulmonary function tests (PFTs), pulmonary vascu-
lar haemodynamics and overall outcomes were reviewed
and recorded for each patient. The date of diagnosis
was identified for each patient, defined as the date on
which clinical evaluation for respiratory symptoms
occurred and radiographic evidence of pulmonary fibro-
sis was present. Survival was calculated from the date of
diagnosis to the date of death or the date of a lung
transplantation, whichever came first. If neither
occurred, survival was defined from the date of diagno-
sis to the date of review.
Computed tomography of the chest
All patients had a CT of the chest performed and each
CT was reviewed by two thoracic radiologists (JJ, JRG)
specifically for the purpose of this study.
All patients had radiographic findings of pulmonary
fibrosis on CT, as evidenced by a combination of reticu-
lar opacities, traction bronchiectasis, architectural distor-
tion, honeycomb change and a peripheral and basilar
predominance to these findings [1,2]. Areas of ground
glass opacities were minor findings if present. The
amount of fibrosis was visually assessed and quantified
on CT as involving < 10%, 10%-40% or > 40% of the
lung parenchyma [12].
The presence of emphysema was visually assessed in
each patient according to a modification of the National
Emphysema Treatment Trial (NETT) scoring system
[13]. The right and left lungs were divided into an
upper portion (apex to aortic arch), a mid portion (aor-
tic arch to inferior pulmonary vein) and a lower portion
(inferior pulmonary vein to diaphragm) and a score was
assigned to describe the amount of lung affected by
emphysema in each portion as follows: score 0 (no
emphysema); score 0.5 (trivial, < 5%); score 1 (mild, 5%-
25%); score 2 (moderate, 26%-50%); score 3 (marked,
51%-75%); and score 4 (severe, > 75%). The scores for
each portion of the right and left lungs (six portions)
were added to obtain the result of a total emphysema
score, with 24 being the maximum possible score.
Additionally, the type of emphysema present was
visually assessed and determined as previously described
[14]. The following patterns were identified: (a) exclu-
sively centrilobular; (b) exclusively paraseptal; (c) centri-
lobular-predominant, in which at least 80% of
emphysema present was in centrilobular pattern; (d)
paraseptal-predominant, in which at least 80% of
emphysema present was in a paraseptal pattern; and (e)
mixed emphysema, in which an equal amount of centri-
lobular and paraseptal emphysema were present.
PFT
All PFT data available was recorded for each patient,
including forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio,
total lung capacity (TLC), functional residual capacity
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carbon monoxide (DLCO). Most patients had multiple
sets of PFT data available for review. For the purpose of
this study, the set of PFT data closest to the date of the
CT was used for analysis.
Pathology
A surgical lung biopsy was obtained in 73 of the 102
patients and was defined as a lung biopsy obtained from
either video assisted thoracoscopy (VATS), an explanted
native lung obtained at the time of lung transplantation,
or an autopsy specimen. The pathology of each patient
was reviewed, and was interpreted according to the con-
sensus statement on idiopathic interstitial pneumonia
(IIP) [2].
Right heart catheterization (RHC)
R H Cw a sp e r f o r m e di n7 6o ft h e1 0 2p a t i e n t s ;i tw a s
performed at the discretion of the treating physician and
was usually performed as part of an evaluation for lung
transplantation. Data measured at the time of RHC
included systolic and diastolic pulmonary artery pres-
sure, pulmonary capillary wedge pressure, cardiac output
and mixed venous oxygen saturation. Mean pulmonary
artery pressure (mPAP) was calculated as the diastolic
pressure plus one-third of the pulse pressure. Pulmonary
vascular resistance was calculated as mPAP minus
wedge pressure, divided by the cardiac output.
Statistical analyses
Data were analysed using Graph Pad Software (CA,
USA). Differences between groups were analysed by
Kruskal-Wallis one way ANOVA with Dunn’s multiple
comparison test or by chi-square test as indicated. Dif-
ferences at P < 0.05 were considered significant.
Results
Overall cohort
The clinical characteristics of the overall cohort of 102
patients with pulmonary fibrosis are shown in Table 1.
There were more males than females and more Cauca-
sian patients than those of other racial groups. Most
patients were on one or more immunosuppressive medi-
cations, with prednisone being the most commonly
used. Approximately two-thirds of patients (n = 71) had
a history of smoking and the remainder were lifelong
non-smokers. RHC was performed in 76 patients and
pulmonary hypertension (defined as mPAP > 25 mm
Hg) was present in 41% of those patients. A surgical
lung biopsy documenting histologically the presence of
pulmonary fibrosis was obtained in the majority of
patients. PFTs indicated a moderately severe restrictive
ventilatory defect and a severe reduction in the DLCO
for the group as a whole.
Emphysema score and survival
The total emphysema score was calculated for each
patient based on the chest computed tomography (CT).
Total emphysema scores ranged from 0 to 22 in this
cohort. The patients were placed into one of three
groups based on the total emphysema score: (a) an
emphysema score of zero (ES 0), indicating no emphy-
sema could be detected (n = 48); (b) an emphysema
score greater than zero but less than or equal to 2 (0 <
ES ≤ 2), consistent with trivial emphysema (n = 26); and
(c) an emphysema score greater than two (ES > 2), con-
sistent with advanced emphysema (n = 28). A chest CT
from a patient with ES > 2 is shown in Figure 1.
Table 2 shows the clinical characteristics of these
three patient groups. There were no differences among
the groups in regards to age, gender, race or medication
use. More patients in the ES > 2 and 0 < ES ≤ 2g r o u p s
had a history of ‘ever-smoking’ but there were very few
Table 1 Characteristics of the overall patient cohort
(n = 102)
Age, years, median [1
st,3
rd] 61 [55, 66]
Gender:
Male, n 66
Female, n 36
Race:
Caucasian, n 69
African-American, n 28
Other, n 5
Medication:
Prednisone, n 88
Azathioprine, n 49
Mycophenolate, n 27
N-Acetylcysteine, n 42
ACE Inhibitor, n 19
Statin, n 45
Smoking history:
Never, n (%) 31 (30)
Ever, n (%) 71 (70)
Right heart catheterization:
Performed, n (%) 76 (75)
PH present, n (%) 31 (41)
Surgical lung biopsy:
Performed, n (%) 73 (71)
UIP, n 60
Fibrotic NSIP, n 13
Pulmonary function tests:
FVC [% predicted; median (1st, 3rd)] 54 [42, 66]
TLC [% predicted; median (1st, 3rd)] 54 [42, 64]
DLCO [% predicted; median (1st, 3rd)] 28 [20, 36]
PH, pulmonary hypertension (defined by mean pulmonary artery pressure
>25 mm Hg); UIP, usual interstitial pneumonia; NSIP, non-specific interstitial
pneumonia; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusing
capacity for carbon monoxide.
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a significantly higher amount of smoking in pack/years
than patients with ES 0 and 0 < ES ≤ 2 (P < 0.001 and
P < 0.05, respectively, Dunn’s multiple comparison test),
and patients with 0 < ES ≤ 2 had smoked more than
patients with ES 0 (P < 0.05). All patients had CT find-
ings of pulmonary fibrosis and there were no differences
in the fibrosis scores between the groups. Similar pro-
portions of patients in each group had RHC performed
but patients with ES >2 and 0 < ES ≤ 2h a dah i g h e r
Figure 1 Chest computed tomogram from a patient with pulmonary fibrosis and an emphysema score of 12. The upper panel shows
advanced predominantly centrilobular emphysema at the level of the aortic arch. The lower panel shows mild ground glass opacities,
substantial reticular opacities, and advanced traction bronchiectasis at the lung bases. Surgical lung biopsy in this patient showed usual
interstitial pneumonia (UIP).
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0.01, respectively). Similar proportions of patients in
each group had undergone a surgical lung biopsy and,
a l t h o u g ht h e r ew a sat r e n dt o w a r d sm o r ef i b r o t i cN S I P
in the ES > 2 group, this was not statistically significant
(P > 0.05). A similar proportion of patients in each
group underwent lung transplantation.
Survival was determined based on the status of each
patient as alive, died or had undergone lung transplanta-
tion. Survival for the three groups of patients is shown in
Figure 2. Median survival [1st, 3rd quartiles] in patients
with ES > 2 was 63 [36, 82] months compared with 29
[18, 49] months in patients having ES 0 and 32 [19, 48]
months in patients with 0 < ES ≤ 2( P <0 . 0 0 1 ) .T h e r e
was no difference in survival between the ES 0 group and
the 0 < ES ≤ 2 group. Kaplan-Meier survival curves of the
three groups of patients revealed a significantly longer
survival for the ES > 2 patients (P = 0.001).
PFTs
PFTs from patients in each of the three patient groups
are shown in Table 3. FVC differed among the three
groups and was higher in the ES > 2 group compared
with the ES 0 group (P < 0.01, Dunn’s multiple compari-
son test). TLC also differed among the three groups and
was higher in the ES > 2 group compared with the 0
<ES ≤ 2a n dE S0g r o u p s( P <0 . 0 5a n dP < 0.001,
respectively). However, although the FVC and TLC were
higher in the ES > 2 group, the percent predicted values
still remained low and were consistent with an overall
Table 2 Clinical characteristics of patients based on emphysema score
Variable ES 0
(n = 48)
0<E S≤ 2
(n = 26)
ES > 2
(n = 28)
P value
Age years; median [1st, 3rd] 62 [58, 68] 61 [53, 67] 57 [51, 62] NS*
Gender:
Male, n
Female, n
31
17
18
8
17
11
NS
†
Race:
Caucasian, n 38 15 16
African-American, n 8 9 11 NS
†
Other, n 221
Medication:
Prednisone, n 40 26 22 NS
†
Azathioprine, n 24 13 12 NS
†
Mycophenolate, n 14 9 4 NS
†
N-Acetylcysteine, n 22 13 7 NS
†
ACE Inhibitor, n 10 6 3 NS
†
Statin, n 20 14 11 NS
†
Smoking:
Current smoker, n (%) 1(2) 2 (7) 4 (14) NS
†
Ever-smoker, n (%) 27 (56) 21 (81) 24 (86) <0.01
†
Pack/years, median [1st, 3rd] 5 [0, 20] 20 [10, 39] 40 [20, 50] <0.0001*
Fibrosis score:
< 10%, n 752
10 - 40%, n 27 16 19 NS
†
> 40%, n 14 5 7
Right heart catheterization:
Performed, n (%) 37 (77) 22 (84) 17 (61) NS
†
Mean PAP mm Hg; median [1st, 3rd] 21 [18, 24] 29 [22, 40] 29 [22, 33] <0.001*
Surgical lung biopsy:
Performed, n (%) 36 (75) 17 (65) 20 (71) NS
†
UIP, n 32 14 14 NS
†
Fibrotic NSIP, n 436
Lung transplantation performed, n (%) 19 (39) 6 (23) 9 (32) NS
†
*Kruskal-Wallis one-way ANOVA.
†Chi-square test.
ES, emphysema score; mean PAP, mean pulmonary artery pressure; UIP, usual interstitial pneumonia; NSIP, non-specific interstitial pneumonia; NS, not significant
(P > 0.05).
Todd et al. Fibrogenesis & Tissue Repair 2011, 4:6
http://www.fibrogenesis.com/content/4/1/6
Page 5 of 9restrictive ventilatory defect. The FEV1/FVC ratio dif-
fered among the three groups and was lower in the ES
> 2 compared to ES 0 group (P < 0.05). DLCO was low
in all groups and did not differ among groups.
2) group",1,0,1,0,0pc,0pc,0pc,0pc>Emphysema type and
survival in the advanced emphysema (ES > 2) group
As patients with ES >2 (n = 28) demonstrated a pro-
longed survival, we further characterized the type of
emphysema present in each patient within this advanced
emphysema group. Patients were placed into three
groups based on the following characterizations: (a)
paraseptal emphysema (n = 7), which included patients
with exclusively paraseptal emphysema and paraseptal-
predominant emphysema; (b) centrilobular emphysema
(n = 13), which included patients with exclusively centri-
lobular emphysema and centrilobular-predominant
emphysema; or (c) mixed emphysema (n = 8).
The clinical characteristics of these three subgroups of
patients are shown in Table 4. There were no differ-
ences among the groups with regards to age or race but
there were more females than males in the centrilobular
group. Patients with centrilobular or mixed emphysema
had a history of higher amounts of smoking (P < 0.05).
A UIP pattern of fibrosis was seen in all subgroups,
although there was a higher proportion of fibrotic NSIP
in the centrilobular group. TLC differed among the
groups but there were no differences in DLCO.
The median survival [1st, 3rd quartiles] of these three
subgroups is shown in Figure 3 and differed among the
subgroups: 75 [58, 85] months in patients with centri-
lobular emphysema, 75 [48, 85] months in patients with
mixed emphysema and 24 [22, 35] months in patients
with paraseptal emphysema (P < 0.01). Kaplan-Meier
survival curves of these subgroups of patients revealed a
significantly longer survival for the centrilobular and
mixed emphysema patients (P < 0.001).
Discussion
We addressed the hypothesis that the prognosis of
patients with pulmonary fibrosis combined with emphy-
sema may be different from patients with pulmonary
fibrosis in the absence of emphysema. We found that
patients with pulmonary fibrosis and advanced emphy-
sema (a modified NETT emphysema score > 2) survived
longer than patients with fibrosis without emphysema
and, furthermore, the prolonged survival benefit in
patients with advanced emphysema was seen in patients
with a substantial centrilobular component to their
emphysema (those with centrilobular emphysema or
mixed emphysema). Patients with fibrosis and trivial
emphysema, as well as patients with advanced paraseptal
emphysema, had survival times similar to those of
patients with fibrosis and no emphysema.
Figure 2 Differences in survival based on emphysema score
[ES]. Median survival differed among the three groups (P < 0.001,
Kruskal-Wallis one-way ANOVA). By Dunn’s multiple comparison
tests, patients with ES > 2 (n = 28) had a longer survival than
patients with ES 0 (n = 48) and patients with 0 < ES ≤ 2( n = 26) (P
< 0.001 and P < 0.01, respectively). (B) Kaplan-Meier survival analyses
revealed significantly longer survival in patients with ES > 2 (P =
0.001; log-rank test).
Table 3 Pulmonary function tests (PFTs)
Variable ES 0
(n = 48)
0<E S≤
2
(n = 26)
ES > 2
(n = 28)
*P
value
FEV1 % predicted; median
[1st, 3rd]
53 [43,
74]
59 [48,
77]
66 [60,
76]
NS
FVC % predicted; median
[1st, 3rd]
47 [38,
63]
50 [43,
62]
60 [55,
73]
< 0.01
FEV1/FVC ratio median
[1st, 3rd]
84 [81,
88]
87 [80,
89]
81 [72,
86]
< 0.05
TLC % predicted; median
[1st, 3
rd]
44 [39,
57]
50 [44,
59]
64 [57,
73]
<.001
DLCO, % predicted; median
[1st, 3rd]
28 [19,
34]
31 [20,
36]
27 [20,
37]
NS
*Kruskal-Wallis one-way ANOVA ES, emphysema score; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity; TLC, total lung capacity;
DLCO, diffusing capacity for carbon monoxide; NS, not significant (P > 0.05).
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combination of emphysema and fibrosis [15-18] and,
similar to our observations, they have reported emphy-
sema located predominantly in the upper lobes, pulmon-
ary fibrosis in the lower lobes and moderate to severe
reductions in the diffusing capacity for carbon monoxide
(DLCO) [15,16]. Reported survival rates for patients with
fibrosis and emphysema have been conflicting and have
been reported to be worse, unchanged or better than for
patients with IPF [16-18]. We expanded the observations
of these previous studies by numerically scoring emphy-
sema in all patients, by adding matching control groups
a n db ya n a l y s i n gt h et y p eo fe m p h y s e m ap r e s e n t .T h e
novelty of our findings, based on our quantitative
approach, is the improved survival in patients with
fibrosis who concurrently had advanced centrilobular
emphysema.
Centrilobular emphysema is almost uniformly caused by
cigarette smoking [9,14] and, as expected, our patients
with advanced emphysema had a substantially higher
amount of past smoking history. Both cigarette smoking
and centrilobular emphysema are associated with pulmon-
ary inflammation [9] and the pro-inflammatory cytokines
seen with cigarette smoking and with emphysema are also
antifibrotic [19]. Paraseptal (or subpleural) emphysema is
also associated with smoking but, additionally, may occur
in non-smokers, is most often found in younger patients
and probably has a different pathogenesis than centrilobu-
lar emphysema [14,20]. In support of these concepts, eight
patients in our overall cohort who were lifelong non-smo-
kers had radiographic findings of paraseptal emphysema.
I tm a yb er e a s o n a b l et oc o n c l u d et h a tt h e r em a yb el e s s
pulmonary inflammation present in patients with parasep-
tal emphysema versus centrilobular. The improved prog-
nosis seen in our patients with advanced centrilobular
emphysema would be consistent with our hypothesis that
a chronic inflammatory process may be partially protective
against the adverse effects of pulmonary fibrosis.
The mechanistic relationship between the develop-
ment of emphysema and the development of fibrosis in
patients with both processes remains unknown. It may
be that this relationship is merely one of coincidence;
patients with a history of smoking develop emphysema
and then subsequently develop fibrosis unrelated to the
presence of emphysema [21]. Alternatively, heavy cigar-
ette smoking may be the common underlying cause for
emphysema and fibrosis in patients with both processes,
as cigarette smoke has been shown to cause fibrosis in
both humans and animals [22,23]. In either instance, the
presence of emphysema will be associated with pulmon-
ary inflammation. Although it may seem paradoxical
that advanced emphysema with fibrosis would improve
Table 4 Clinical characteristics of patients with emphysema score (ES) > 2 based on type of emphysema
Variable ES > 2
Paraseptal
(n =7 )
ES > 2
Mixed
(n =8 )
ES > 2
Centrilobular
(n = 13)
P value
Age years; median [1st, 3rd] 57 [51, 63] 59 [57, 63] 54 [49, 62] NS*
Gender:
Male, n 7 8 2 < 0.001
†
Female, n 00 1 1
Race:
Caucasian, n 36 7
African-American, n 32 6 N S
†
Other, n 10 0
Smoking packs/years; median [1st, 3rd] 14 [0, 38] 40 [38, 46] 45 [25, 60] <0.05*
Right heart catheterization:
Performed, n (%) 5 (71) 6 (75) 6 (46) NS
†
Mean PAP mm Hg; median [1st, 3rd] 32 [21, 34] 31 [29, 33] 25 [22, 31] NS*
Surgical lung biopsy:
Performed, n (%) 6 (86) 5 (63) 9 (70) NS
†
UIP, n 6 4 4 <0.05
†
Fibrotic NSIP, n 01 5
FVC % predicted; median, [1st, 3rd] 57 [50, 60] 59 [51, 63] 71 [58, 84] NS*
TLC % predicted; median, [1st, 3rd] 58 [51, 64] 60 [52, 69] 72 [64, 86] 0.05
DLCO % predicted; median, [1st, 3rd] 25 [21, 31] 28 [23, 34] 27 [18, 37] NS*
*Kruskal-Wallis one-way ANOVA;
†Chi-square test.
Paraseptal, paraseptal emphysema; mixed, mixed centrilobular and paraseptal emphysema; centrilobular, centrilobular emphysema; mean PAP, mean pulmonary
artery pressure; UIP, usual interstitial pneumonia; NSIP, non-specific interstitial pneumonia; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusing
capacity for carbon monoxide; NS, not significant (P > 0.05).
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inflammation may be partially protective.
The patients in our study who had advanced emphy-
sema did have higher lung volumes (vital capacity and
TLC) than patients without emphysema, a finding not
surprising due to the presence of emphysema and a
finding which had been previously reported in patients
with emphysema and fibrosis [16]. One could argue that
these higher lung volumes may contribute to the
improved survival, although the DLCO,a ni n d i c a t o ro f
abnormal gas exchange that is linked to mortality in
pulmonary fibrosis, was very low in all groups [24]. The
FEV1/FVC ratio was also lower in the advanced emphy-
sema group but the overall physiology pattern of PFTs
was still consistent with a restrictive ventilatory defect, a
pattern seen in pulmonary fibrosis. This restrictive PFT
pattern indicates that, despite the presence of advanced
emphysema in this group, the effects of the fibrotic
component dominate from a physiologic standpoint.
An issue which warrants discussion is our inclusion of
patients with fibrotic NSIP. We believe inclusion of these
patients was appropriate for several reasons which
include: the occurrence in many instances of both NSIP
and UIP patterns in different lobes from the same patient
[25]; the fact that the majority of patients with UIP on
biopsy and explant specimens will have NSIP areas [26];
and the known observation that smoking may cause an
NSIP pattern of fibrosis [27]. Additionally, patients with
U I Po rN S I Pb u taD L CO < 35% predicted (median DLCO
in our overall cohort was 28% predicted) had similar out-
comes irrespective of their pathologic pattern [28].
A limitation to our study is its observational and ret-
rospective design. Another limitation is that we did not
measure the levels of pulmonary or systemic pro- or
anti-inflammatory or pro- or anti-fibrotic cytokines.
This limitation will be addressed in our future studies.
In summary, we have demonstrated that patients with
pulmonary fibrosis and advanced emphysema (based on a
modified NETT emphysema score of greater than 2) have
a better prognosis than patients with pulmonary fibrosis
without emphysema or with trivial amounts of emphy-
sema. Furthermore, this improved prognosis was limited
to patients with a substantial centrilobular component to
their emphysema, as patients with isolated advanced para-
septal emphysema had outcomes similar to patients with-
out emphysema. The precise mechanisms responsible for
this improved survival are unknown but our data support
the hypothesis that pulmonary inflammation resulting
from the presence of emphysema may be partially protec-
tive against the deleterious effects of pulmonary fibrosis.
Conclusions
We have demonstrated that patients with pulmonary
fibrosis and advanced centrilobular emphysema, a well
established chronic inflammatory condition of the lung,
have a better prognosis than patients with pulmonary
fibrosis without emphysema or those with fibrosis and
trivial amounts of emphysema. Although the precise
mechanisms responsible for this improved survival are
not known, our data support the hypothesis that pul-
monary inflammation may be partially protective against
the usual deteriorating clinical course of patients with
idiopathic pulmonary fibrosis.
Figure 3 Differences in survival among subgroups of patients
with advanced emphysema (ES > 2) based on emphysema
type. (A) Median survival differed among the three groups (P <
0.01; Kruskal-Wallis one-way ANOVA). By Dunn’s multiple comparison
tests, patients with centrilobular emphysema (n = 13) or mixed
emphysema (n = 8) had a longer survival than patients with
paraseptal emphysema (n = 7)(P < 0.01 and P < 0.05, respectively).
There was no difference in survival between the centrilobular group
and the mixed emphysema group. (B) Kaplan-Meier survival curves
of these subgroups of patients revealed a significantly longer
survival for the centrilobular and mixed emphysema patients (P <
0.001, log-rank test).
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